This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca, Pfizer, and Takeda Oncology.

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Heather Wakelee, MD
Stanford Health Care

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC
The University of Texas MD Anderson Cancer Center

Learn about the recent updates in the world of genetic testing and targeted therapies for non–small cell lung cancer. It’s vital that advanced practitioners in oncology have the latest knowledge on EGFR, ALK, and BRAF inhibitors, as well as acquired resistance mutations, to help patients from diagnosis through treatment.


Download Transcript


Download Slides


These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.